Development Cellular Models of the Ear and Nose to Study the Mechanisms of Hearing

Hearing Loss, GJB2, Cis Regulation, DFNB1 Clinical Trial

— CMAG  

Official title:

Development of Cellular Models of the Ear and Nose From Patient Samples to Study the Mechanisms of Hearing

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04823195
• Other study ID #: 29BRC20.0331
• Status: Recruiting
• Start date: June 15, 2021
• Est. completion date: June 15, 2024

Study information

• Verified date: September 2023
• Source: University Hospital, Brest
• Contact: Rémi Marianowski
• Phone: 02-98-22-33-78
• Email: remi.marianowski[@]chu-brest.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Development of cells culturesissued from Nose and Ear to study auditory mecanisms.

Study of the cis-Modulation of the gene GJB2 for the patients with early presbycusis to identify the genetic cause of hearing loss.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: June 15, 2024
• Est. primary completion date: June 15, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Hearing loss Presbycusis Exostosis

Exclusion Criteria:

• Genetic hearing loss

Related Conditions & MeSH terms

• Hearing Loss
• Hearing Loss, GJB2, Cis Regulation, DFNB1

Locations

Country	Name	City	State
France	CHRU de Brest	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	GJB2 cis regulation	Culture cell model	2 years